• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medpace (MEDP) Q2 Earnings Report Preview: What To Look For

By: StockStory
July 19, 2025 at 23:01 PM EDT

MEDP Cover Image

Clinical research company Medpace Holdings (NASDAQ: MEDP) will be reporting results this Monday after market hours. Here’s what to expect.

Medpace beat analysts’ revenue expectations by 6% last quarter, reporting revenues of $558.6 million, up 9.3% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts’ organic revenue estimates and an impressive beat of analysts’ EPS estimates.

Is Medpace a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Medpace’s revenue to grow 2.6% year on year to $542 million, slowing from the 14.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.00 per share.

Medpace Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medpace has missed Wall Street’s revenue estimates five times over the last two years.

With Medpace being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for life sciences tools & services stocks. However, the whole sector has been hit hard over the last month as stocks in Medpace’s peer group are down 2.5% on average. Medpace’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $301.61 (compared to the current share price of $311.86).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

More News

View More
3 Streaming Stocks to Watch as Subscribers Drive Growth
Today 10:41 EDT
Via MarketBeat
Tickers DIS NFLX ROKU
America Wants Drone Dominance: Are These Stocks Ready to Soar?
Today 9:41 EDT
Via MarketBeat
Topics Government
Tickers AVAV GD KTOS LMT
3 Retailers Poised to Outmaneuver Tariff and Recession Concerns
Today 8:25 EDT
Via MarketBeat
Topics ETFs Economy Government
Tickers BOOT BOSSY GLBE SHOP
PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
July 19, 2025
Via MarketBeat
Topics World Trade
Tickers PEP
Is J.B. Hunt Stock a Sleeping Giant Heading Into 2026?
July 19, 2025
Via MarketBeat
Tickers JBHT
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap